BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy

BeOne Medicines Ltd. (NASDAQ: ONC ) shares are trading lower on Tuesday as the company shared topline results from its Phase 3 MANGROVE trial for BRUKINSA, a treatment for mantle cell lymphoma.

BeOne Medicines MANGROVE Trial Results For BRUKINSA The MANGROVE study demonstrated that BRUKINSA plus rituximab reduced the risk of progression or death by 43% compared to the standard treatment of bendamustine plus rituximab.

This pivotal trial marks a significant advancement in chemotherapy-free treatment options for patients with mantle cell lymphoma, with full results expected to be presented at an upcoming medical meeting.

The oncology-focused company said that MANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusions.

Read Also: BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer Full results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for the second half of 2026.

ONC Technical Analysis: Trend, RSI And Key Levels BeOne Medicines stock is currently trading at $286.41, which is about 1.9% below its 50-day simple moving average (SMA) of $290.57.

The stock is also 5.7% below its 100-day SMA of $302.51, indicating a bearish trend in the medium term.

The Relative Strength Index (RSI) is at 53.15, suggesting that the stock is in a neutral position, neither overbought nor oversold.

This indicates that there could be potential for further movement in either direction, depending on upcoming market conditions and investor sentiment.

Key Resistance: $312.00 — a nearby level where rebounds can stall.

Key Support: $254.00 — a nearby level where buyers previously stepped in.

Analyst Consensus & Recent Actions: The stock carries a Buy rating with an average price target of $384.38.

Recent analyst moves include: RBC Capital: Outperform (Raises Target to $436.00) (June 2) Leerink Partners: Outperform (Raises Target to $367.00) (May 15) How ONC Ranks On Value And Momentum Below is the Edge scorecard for BeOne Medicines shares, highlighting its strengths and weaknesses compared to the broader market: Value Rank: 45.24 — The stock is trading at a moderate valuation relative to its peers.

Momentum Rank: 37.66 — The stock is showing weak performance indicators.

The Verdict: BeOne Medicines shares’ Edge signal reveals a mixed profile with moderate value and weak momentum.

ONC Price Action: BeOne Medicines shares were down 1.84% at $284.64 at the time of publication on Tuesday, according to Pro data.

Read Also: JPMorgan Says Crypto Regulatory Clarity Matters Only If 'Paired With Durable Safeguards,' Flags Stablecoin Yield Risks Image via Shutterstock/ K_E_N